Pharma BD Deal Intelligence

AbbVie Inc. / Pharmacyclics Inc.

2015 · Acquisition/Merger · $21.0B · Complete

Announcement Sentiment

Neutral / mixed

Outcome Score

Worked — the deal delivered on its rationale.

AbbVie acquired Pharmacyclics for approximately $21 billion ($261.25 per share in a 58% cash / 42% stock mix), gaining full ownership of Imbruvica (ibrutinib), a first-in-class BTK inhibitor with four approved indications in hematologic malignancies and over 50 ongoing clinical studies.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Mar 04, 2015
Closed May 26, 2015
Deal value $21.0B
Deal type Acquisition/Merger
Therapeutic area Hematology, Oncology
Indications Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Key assets Imbruvica (ibrutinib)
Mechanism Bruton's tyrosine kinase (BTK) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals